We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+8.84%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.5B
AUM Growth
+$2.79M
Cap. Flow
+$38.8M
Cap. Flow %
2.58%
Top 10 Hldgs %
78.81%
Holding
41
New
6
Increased
3
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
NGNE icon
Neurogene
NGNE
+$28.7M
2
SEPN
Septerna Inc
SEPN
+$13.1M
3
BEAM icon
Beam Therapeutics
BEAM
+$12.1M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$11.7M
5
MRNA icon
Moderna
MRNA
+$8.36M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$20.9M
2
VCYT icon
Veracyte
VCYT
+$14.8M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.89M
4
GRAL
GRAIL Inc
GRAL
+$4.82M
5
RNAM
Avidity Biosciences
RNAM
+$1.66M

Sector Composition

Rank Sector Weight
1 Healthcare 99.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FDMT icon
26
4D Molecular Therapeutics
FDMT
$527M
$6.41M 0.43%
1,150,000
– –
SNDX icon
27
Syndax Pharmaceuticals
SNDX
$1.7B
$6.28M 0.42%
475,000
– –
TSVT
28
DELISTED
2seventy bio
TSVT
$5.88M 0.39%
2,000,000
– –
IPSC icon
29
Century Therapeutics
IPSC
$357M
$5.24M 0.35%
5,190,506
+1,978,190
+62% +$2.69M
FTRE icon
30
Fortrea Holdings
FTRE
$1.8B
$5.13M 0.34%
+275,000
New +$5.36M
CTNM
31
Contineum Therapeutics
CTNM
$599M
$4.35M 0.29%
296,666
– –
TNGX icon
32
Tango Therapeutics
TNGX
$4.43B
$3.67M 0.24%
1,188,349
– –
ABSI icon
33
Absci
ABSI
$1.34B
$2.55M 0.17%
973,260
– –
PACB icon
34
Pacific Biosciences
PACB
$441M
$1.9M 0.13%
1,035,859
– –
RXRX icon
35
Recursion Pharmaceuticals
RXRX
$1.69B
$1.12M 0.07%
+165,323
New +$1.11M
PRME icon
36
Prime Medicine
PRME
$508M
$1.07M 0.07%
367,175
– –
GLUE icon
37
Monte Rosa Therapeutics
GLUE
$1.3B
$597K 0.04%
86,014
– –
DNA icon
38
Ginkgo Bioworks
DNA
$584M
$358K 0.02%
36,493
– –
KRON
39
DELISTED
Kronos Bio
KRON
$118K 0.01%
123,839
– –
GRAL
40
GRAIL Inc
GRAL
$3.02B
– –
-350,000
Closed -$4.82M
EXAI
41
DELISTED
Exscientia Plc American Depositary Shares
EXAI
– –
-213,900
Closed -$1.04M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Casdin Capital held 41 positions worth $1.5B, up 0.19% from $1.5B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Casdin Capital's Q4 2024 filing shows 6 new, 3 increased, 5 reduced and 2 closed positions. Its largest new stake was Septerna Inc: 553,268 shares worth $12.7M. The largest sale was Revolution Medicines, an estimated $20.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • Casdin Capital's largest Q4 2024 buy was Septerna Inc: 553,268 shares worth $12.7M.
  • Casdin Capital added most to Neurogene in Q4 2024, an estimated $28.7M increase.
  • Casdin Capital's biggest Q4 2024 reduction was Revolution Medicines, cutting an estimated $20.9M.
  • Casdin Capital fully exited GRAIL Inc in Q4 2024, selling an estimated $4.82M.
  • Casdin Capital's ten largest holdings make up 79% of its $1.5B portfolio in Q4 2024.
  • Casdin Capital opened 6 new positions and closed 2 in Q4 2024.
  • Casdin Capital's portfolio value rose 0.19% quarter-over-quarter to $1.5B.

Based on Casdin Capital's 13F filing for Q4 2024, filed 14 Feb 2025.